|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
JA K1 and JA K2 inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Jakafi
|
|
gptkbp:category
|
gptkb:unknown
Category C
|
|
gptkbp:class
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase 3
hematological malignancies
chronic inflammatory diseases
|
|
gptkbp:combatants
|
high affinity for JA K1 and JA K2
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to ruxolitinib
active serious infections
|
|
gptkbp:discovered_by
|
gptkb:Incyte_Corporation
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ruxolitinib
|
|
gptkbp:ingredients
|
C17 H18 N4 O5 S
|
|
gptkbp:interacts_with
|
live vaccines
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
treatment of myelofibrosis
treatment of polycythemia vera
|
|
gptkbp:lifespan
|
3 hours
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research
|
gptkb:healthcare_organization
gptkb:Crohn's_disease
gptkb:systemic_lupus_erythematosus
gptkb:ulcerative_colitis
gptkb:psychologist
gptkb:rheumatoid_arthritis
gptkb:drug
dermatitis
psoriasis
atopic dermatitis
|
|
gptkbp:side_effect
|
gptkb:fandom
dizziness
fatigue
headache
nausea
diarrhea
increased risk of infections
thrombocytopenia
elevated liver enzymes
|
|
gptkbp:type_of
|
941678-49-5
|
|
gptkbp:bfsParent
|
gptkb:Jakavi
|
|
gptkbp:bfsLayer
|
4
|